European Journal of Medical Research (Nov 2023)

The molecular landscape of neurological disorders: insights from single-cell RNA sequencing in neurology and neurosurgery

  • Wireko Andrew Awuah,
  • Arjun Ahluwalia,
  • Shankaneel Ghosh,
  • Sakshi Roy,
  • Joecelyn Kirani Tan,
  • Favour Tope Adebusoye,
  • Tomas Ferreira,
  • Hareesha Rishab Bharadwaj,
  • Vallabh Shet,
  • Mrinmoy Kundu,
  • Amanda Leong Weng Yee,
  • Toufik Abdul-Rahman,
  • Oday Atallah

DOI
https://doi.org/10.1186/s40001-023-01504-w
Journal volume & issue
Vol. 28, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Single-cell ribonucleic acid sequencing (scRNA-seq) has emerged as a transformative technology in neurological and neurosurgical research, revolutionising our comprehension of complex neurological disorders. In brain tumours, scRNA-seq has provided valuable insights into cancer heterogeneity, the tumour microenvironment, treatment resistance, and invasion patterns. It has also elucidated the brain tri-lineage cancer hierarchy and addressed limitations of current models. Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis have been molecularly subtyped, dysregulated pathways have been identified, and potential therapeutic targets have been revealed using scRNA-seq. In epilepsy, scRNA-seq has explored the cellular and molecular heterogeneity underlying the condition, uncovering unique glial subpopulations and dysregulation of the immune system. ScRNA-seq has characterised distinct cellular constituents and responses to spinal cord injury in spinal cord diseases, as well as provided molecular signatures of various cell types and identified interactions involved in vascular remodelling. Furthermore, scRNA-seq has shed light on the molecular complexities of cerebrovascular diseases, such as stroke, providing insights into specific genes, cell-specific expression patterns, and potential therapeutic interventions. This review highlights the potential of scRNA-seq in guiding precision medicine approaches, identifying clinical biomarkers, and facilitating therapeutic discovery. However, challenges related to data analysis, standardisation, sample acquisition, scalability, and cost-effectiveness need to be addressed. Despite these challenges, scRNA-seq has the potential to transform clinical practice in neurological and neurosurgical research by providing personalised insights and improving patient outcomes.

Keywords